<DOC>
	<DOCNO>NCT00015821</DOCNO>
	<brief_summary>Phase II trial study effectiveness thalidomide treat patient myelofibrosis . Thalidomide may stop growth myelofibrosis stop blood flow cancer cell .</brief_summary>
	<brief_title>Thalidomide Treating Patients With Myelofibrosis</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To investigate whether thalidomide , potent inhibitor angiogenic fibrogenic growth factor , effective therapeutic agent patient MMM . Specifically , ass whether thalidomide improve anemia and/or organomegaly patient MMM . II . To assess effect thalidomide myelofibrotic stroma respect microvascular architecture angiogenesis , collagen reticulin deposition , expression mediate growth factor bFGF , TGF-b , PDGF , respective receptor . OUTLINE : This multicenter study . Patients receive oral thalidomide daily 1 year absence disease progression unacceptable toxicity . Patients stable respond disease may receive 1 additional year therapy . Patients follow every 6 month 5 year study entry .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Histologically confirm myelofibrosis myeloid metaplasia Agnogenic myeloid metaplasia Postpolycythemic myeloid metaplasia Postthrombocythemic myeloid metaplasia No metastatic carcinoma , lymphoma , myelodysplasia , hairy cell leukemia , mast cell disease , acute leukemia ( include M7 ) , acute myelofibrosis No chromosomal translocation ( 9 ; 22 ) bcr/abl gene rearrangement Presence reticulin fibrosis bone marrow leukoerythroblastosis dacrocytosis peripheral blood Presence anemia ( hemoglobin le 10 g/dL ) , palpable splenomegaly , hepatomegaly Performance status ECOG 02 Absolute neutrophil count great 750/mm^3 Platelet count le 400,000/mm^3 WBC less 50,000/mm^3 Bilirubin great 2 mg/dL ( total bilirubin elevate , direct bilirubin must normal ) AST great 3 time upper limit normal ( ULN ) Alkaline phosphatase great 3 time ULN Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min Not pregnant nursing Negative pregnancy test Fertile woman must use least 1 highly active method AND 1 additional effective method contraception least 4 week study , study , least 4 week study Fertile men must use effective contraception study least 4 week study No uncontrolled infection No concurrent condition would preclude study No peripheral neuropathy At least 1 month since prior interferon , pirfenidone , anagrelide , epoetin alfa At least 1 month since prior hydroxyurea chemotherapy At least 1 month since prior corticosteroid androgen derivative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>